In a landmark step to strengthen Pakistan’s pharmaceutical and healthcare regulation, the Drug Regulatory Authority of Pakistan (DRAP) has launched a series of bold reforms. The initiative has been taken under the direct leadership of Prime Minister Shehbaz Sharif and Federal Minister for Health, Dr. Mustafa Kamal.

The reforms aim to ensure transparency, affordability, and accessibility of essential medicines. DRAP’s new policy focuses on improving regulatory mechanisms, streamlining approval processes, and enhancing oversight of pharmaceutical manufacturing standards.

According to officials, the transformation involves implementing digital systems for drug tracking, enhancing pricing transparency, and cracking down on counterfeit or substandard medications in the market.

This initiative reflects the government’s strong commitment to improving public health services and making Pakistan’s healthcare sector more efficient and accountable. The move is also expected to boost investor confidence in local pharma production and encourage innovation in drug development and distribution.